AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12681546 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment via transsylvian transinsular approach
Number of subjects: 66
Study 12681546 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 66
Study 10807818 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-positive group
Number of subjects: 116
Study 10807818 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-positive admitted patients
Number of subjects: 116
Study 10807818 — intervention group
Group type: COMPARATOR
Intervention: All patients
Number of subjects: 116
Study 8819246 — intervention group
Group type: EXPERIMENTAL
Intervention: High-purity factor IX (HP-FIX)
Number of subjects: 0
Study 8819246 — intervention group
Group type: COMPARATOR
Intervention: Prothrombin complex concentrate (PCC)
Number of subjects: 0
Study 1284093 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (0.5 mg/kg)
Number of subjects: 20
Study 1284093 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium (0.1 mg/kg)
Number of subjects: 20
Study 3933262 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural nicomorphine
Number of subjects: 163
Study 3933262 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular opiates
Number of subjects: 163
Study 3933262 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural group
Number of subjects: 163
Study 3933262 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular group
Number of subjects: 163
Study 30156361 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized terbutaline combined with ipratropium bromide (5 mg terbutaline + 0.5 mg IB)
Number of subjects: 232
Study 30156361 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline alone (5 mg)
Number of subjects: 232
Study 30156361 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 232
Study 29843509 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (80 mg) plus Palonosetron (0.075 mg)
Number of subjects: 100
Study 29843509 — intervention group
Group type: COMPARATOR
Intervention: Palonosetron (0.075 mg)
Number of subjects: 100
Study 26900902 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 2629
Study 26900902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2629
Study 26900902 — intervention group
Group type: COMPARATOR
Intervention: Dapivirine vaginal ring and Placebo
Number of subjects: 2629
Study 24957552 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant hormone therapy
Number of subjects: 481
Study 23302159 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy
Number of subjects: 92
Study 23302159 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 92
Study 21488379 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy based on level of kidney function activity
Number of subjects: 0
Study 18580346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol 1 g
Number of subjects: 40
Study 18580346 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl 100 ml (placebo)
Number of subjects: 40
Study 16078956 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial hypotension (PPH)
Number of subjects: 179
Study 16078956 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial systolic blood pressure (SBP) of 120 mmHg or less
Number of subjects: 179
Study 16078956 — intervention group
Group type: EXPERIMENTAL
Intervention: Low diastolic blood pressure (DBP)
Number of subjects: 179
Study 16078956 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 179
Study 11914297 — intervention group
Group type: EXPERIMENTAL
Intervention: Random effects model OR
Number of subjects: 1843
Study 11914297 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed effects model OR
Number of subjects: 1843
Study 11914297 — intervention group
Group type: EXPERIMENTAL
Intervention: Random effects model RR
Number of subjects: 1843
Study 11914297 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed effects RD
Number of subjects: 1843
Study 11914297 — intervention group
Group type: EXPERIMENTAL
Intervention: Random effects RD
Number of subjects: 1843
Study 9918521 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CE) 0.625 mg
Number of subjects: 28
Study 9918521 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg
Number of subjects: 28
Study 9918521 — intervention group
Group type: EXPERIMENTAL
Intervention: CE combined with simvastatin
Number of subjects: 28
Study 9918521 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 28
Study 7486184 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane at 0.5 MAC
Number of subjects: 21
Study 7486184 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 0.5 MAC
Number of subjects: 21
Study 7486184 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 0.5 MAC
Number of subjects: 21
Study 7486184 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane at 1.5 MAC
Number of subjects: 21
Study 7486184 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 1.5 MAC
Number of subjects: 21
Study 7486184 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 1.5 MAC
Number of subjects: 21
Study 2254502 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal problem-solving skills improvement
Number of subjects: 36
Study 7380201 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg a.c.) added to pancreatic enzyme therapy
Number of subjects: 8
Study 7380201 — intervention group
Group type: COMPARATOR
Intervention: Pancreatic enzyme therapy
Number of subjects: 8
Study 31233843 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg Fentanyl Sublingual Tablets (FST)
Number of subjects: 114
Study 31233843 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg Subcutaneous Morphine (SCM)
Number of subjects: 114
Study 28064386 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief supportive‐expressive therapy (SET)
Number of subjects: 77
Study 28064386 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 77
Study 28064386 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SET and control)
Number of subjects: 77
Study 26010143 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA extract (200 mg GABA) with alcohol drinking (GA)
Number of subjects: 0
Study 26010143 — intervention group
Group type: COMPARATOR
Intervention: Placebo intake and alcohol drinking (PA)
Number of subjects: 0
Study 24334868 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried strawberry (FDS) supplementation (2 cups of FDS beverage daily for 6 weeks)
Number of subjects: 36
Study 24334868 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried strawberry (FDS) supplementation
Number of subjects: 36
Study 24334868 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder with strawberry flavor
Number of subjects: 36
Study 21575097 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-component compression (2CC) system
Number of subjects: 30
Study 21575097 — intervention group
Group type: COMPARATOR
Intervention: Inelastic multicomponent compression bandages (IMC)
Number of subjects: 30
Study 21575097 — intervention group
Group type: COMPARATOR
Intervention: Both groups (2CC and IMC)
Number of subjects: 30
Study 19564767 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral fluoroscopic guidance (L guidance)
Number of subjects: 20
Study 19564767 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lateral and AP fluoroscopic guidance (AP + L guidance)
Number of subjects: 20
Study 17076961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue exposure treatment
Number of subjects: 63
Study 17076961 — intervention group
Group type: COMPARATOR
Intervention: Standard cognitive-behavioral treatment
Number of subjects: 63
Study 17076961 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 63
Study 15324297 — intervention group
Group type: EXPERIMENTAL
Intervention: Present tense be use in children with SLI
Number of subjects: 22
Study 15324297 — intervention group
Group type: COMPARATOR
Intervention: Present tense be use in typically developing children (control group)
Number of subjects: 22
Study 11528199 — intervention group
Group type: COMPARATOR
Intervention: Desmopressin
Number of subjects: 40
Study 11528199 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 40
Study 9754456 — intervention group
Group type: EXPERIMENTAL
Intervention: Profiled Hemodialysis (PHD)
Number of subjects: 11
Study 9754456 — intervention group
Group type: COMPARATOR
Intervention: Standard Hemodialysis (SHD)
Number of subjects: 11
Study 7850227 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive method for cholesterol extraction from the surface layers of the epidermis
Number of subjects: 105
Study 3232784 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative crystalloid (1000 ml compound sodium lactate solution)
Number of subjects: 100
Study 3232784 — intervention group
Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 100
Study 8198262 — intervention group
Group type: COMPARATOR
Intervention: Spinal block with 0.5% hyperbaric bupivacaine, 2.5 mL
Number of subjects: 42
Study 8198262 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential combined spinal-epidural block with 1.5 mL of 0.5% hyperbaric bupivacaine and additional doses if needed
Number of subjects: 42
Study 678733 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental social work service (task‐centered casework)
Number of subjects: 261
Study 678733 — intervention group
Group type: COMPARATOR
Intervention: Control (routine follow‐up service)
Number of subjects: 261
Study 678733 — intervention group
Group type: EXPERIMENTAL
Intervention: Excluded group (not part of the trial)
Number of subjects: 261
Study 30316627 — intervention group
Group type: EXPERIMENTAL
Intervention: hf‐rTMS
Number of subjects: 26
Study 30316627 — intervention group
Group type: COMPARATOR
Intervention: sham hf‐rTMS
Number of subjects: 26
Study 28857852 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula at 60 L/min
Number of subjects: 12
Study 25584489 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilotumumab (7.5 and 15 mg/kg)
Number of subjects: 0
Study 25584489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25584489 — intervention group
Group type: EXPERIMENTAL
Intervention: Low exposure to Rilotumumab
Number of subjects: 0
Study 24315810 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with MS
Number of subjects: 20
Study 24315810 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy participants)
Number of subjects: 20
Study 23027910 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption
Number of subjects: 30433
Study 23027910 — intervention group
Group type: EXPERIMENTAL
Intervention: High alcohol consumption
Number of subjects: 30433
Study 23027910 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge drinking among moderate drinkers
Number of subjects: 30433
Study 23027910 — intervention group
Group type: COMPARATOR
Intervention: Low alcohol consumption
Number of subjects: 30433
Study 20003306 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and Vegetable Index (FVI)
Number of subjects: 158
Study 20003306 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet Index (MDI)
Number of subjects: 158
Study 20003306 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of FVI with ozone
Number of subjects: 158
Study 20003306 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of MDI with ozone
Number of subjects: 158
Study 20003306 — intervention group
Group type: COMPARATOR
Intervention: Dietary effect
Number of subjects: 158
Study 18090435 — intervention group
Group type: EXPERIMENTAL
Intervention: R-flurbiprofen 400 mg/d
Number of subjects: 48
Study 18090435 — intervention group
Group type: EXPERIMENTAL
Intervention: R-flurbiprofen 800 mg/d
Number of subjects: 48
Study 18090435 — intervention group
Group type: EXPERIMENTAL
Intervention: R-flurbiprofen 1600 mg/d
Number of subjects: 48
Study 18090435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 18090435 — intervention group
Group type: EXPERIMENTAL
Intervention: R-flurbiprofen (all doses)
Number of subjects: 48
Study 12819938 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 12819938 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 12819938 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors
Number of subjects: 0
Study 12819938 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian suppression
Number of subjects: 0
Study 11075969 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg misoprostol
Number of subjects: 143
Study 11075969 — intervention group
Group type: COMPARATOR
Intervention: 3 mg dinoprostone
Number of subjects: 143
Study 8837563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraaortic balloon counterpulsation (IABP) for 48 hours, n = 23
Number of subjects: 45
Study 8837563 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy, n = 22 (control)
Number of subjects: 45
Study 1331217 — intervention group
Group type: EXPERIMENTAL
Intervention: Repirinast 300 mg twice daily for 7 days
Number of subjects: 14
Study 1331217 — intervention group
Group type: COMPARATOR
Intervention: Cromolyn 40 mg single dose
Number of subjects: 14
Study 1331217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3913725 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoprofen calcium
Number of subjects: 100
Study 3913725 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 100
Study 31213447 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine-70% isopropanol
Number of subjects: 4100
Study 31213447 — intervention group
Group type: COMPARATOR
Intervention: 5% povidone iodine-69% ethanol
Number of subjects: 4100
Study 28974833 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 150
Study 28974833 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 150
Study 28974833 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 150
Study 25782770 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training combined with cognitive remediation (30min, 3 times/wk for endurance training; 30min, 2 times/wk for CACR training starting from week 6)
Number of subjects: 22
Study 25782770 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training combined with cognitive remediation
Number of subjects: 22
Study 25782770 — intervention group
Group type: COMPARATOR
Intervention: Table soccer with cognitive remediation (same CACR training as endurance group)
Number of subjects: 22
Study 23616624 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib consolidation therapy (20 doses over 21 weeks)
Number of subjects: 370
Study 23616624 — intervention group
Group type: COMPARATOR
Intervention: No consolidation (control group)
Number of subjects: 370
Study 23616624 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib consolidation therapy
Number of subjects: 370
Study 20673648 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum remedies (Nux Vomica or Coffea Cruda, 30c doses)
Number of subjects: 54
Study 20673648 — intervention group
Group type: COMPARATOR
Intervention: Placebo pellets
Number of subjects: 54
Study 18817530 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimized immunosuppression
Number of subjects: 0
Study 18817530 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolerance application
Number of subjects: 0
Study 17188782 — intervention group
Group type: EXPERIMENTAL
Intervention: More-aerated snack (0.45 kcal/ml)
Number of subjects: 28
Study 17188782 — intervention group
Group type: COMPARATOR
Intervention: Less-aerated snack (1.00 kcal/ml)
Number of subjects: 28
Study 17188782 — intervention group
Group type: COMPARATOR
Intervention: Both snacks served in a bowl and opaque bag
Number of subjects: 28
Study 17188782 — intervention group
Group type: EXPERIMENTAL
Intervention: Both snacks
Number of subjects: 28
Study 15497055 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention workshop
Number of subjects: 320
Study 15497055 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom distribution program
Number of subjects: 320
Study 15497055 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 320
Study 11740736 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valganciclovir
Number of subjects: 148
Study 11740736 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir
Number of subjects: 148
Study 9249617 — intervention group
Group type: EXPERIMENTAL
Intervention: Curdlan sulfate (CRDS) 50 mg/70 Kg
Number of subjects: 21
Study 9249617 — intervention group
Group type: EXPERIMENTAL
Intervention: Curdlan sulfate (CRDS) 100 mg/70 Kg
Number of subjects: 21
Study 9249617 — intervention group
Group type: EXPERIMENTAL
Intervention: Curdlan sulfate (CRDS) 200 mg/70 Kg
Number of subjects: 21
Study 9249617 — intervention group
Group type: COMPARATOR
Intervention: Historical control (untreated)
Number of subjects: 21
Study 9249617 — intervention group
Group type: EXPERIMENTAL
Intervention: Curdlan sulfate (CRDS)
Number of subjects: 21
Study 8325044 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac (400 mg/day)
Number of subjects: 108
Study 8325044 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (150 mg/day)
Number of subjects: 108
Study 3527706 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AT)
Number of subjects: 59
Study 3527706 — intervention group
Group type: COMPARATOR
Intervention: Oxaprotiline (OT)
Number of subjects: 59
Study 3527706 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 59
Study 31289053 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site sexual health and relationships services
Number of subjects: 2105
Study 31289053 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff safeguarding training about sexual health and relationships
Number of subjects: 2105
Study 31289053 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex and relationships education
Number of subjects: 2105
Study 31289053 — intervention group
Group type: EXPERIMENTAL
Intervention: Student-led sexual health action groups
Number of subjects: 2105
Study 27819445 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day brief mindfulness training incorporating instruction in both attention monitoring and acceptance
Number of subjects: 147
Study 27819445 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training incorporating attention monitoring instruction only
Number of subjects: 147
Study 27819445 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training condition
Number of subjects: 147
Study 27819445 — intervention group
Group type: COMPARATOR
Intervention: Active reading-control condition
Number of subjects: 147
Study 25733652 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron plus placebo
Number of subjects: 321
Study 25733652 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA/EPA plus placebo
Number of subjects: 321
Study 25733652 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron plus DHA/EPA
Number of subjects: 321
Study 25733652 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus placebo
Number of subjects: 321
Study 23929243 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological therapy (TNF-α inhibitors)
Number of subjects: 75
Study 23929243 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted physiotherapy program conducted twice a week for 12 weeks
Number of subjects: 75
Study 23929243 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted physiotherapy program
Number of subjects: 75
Study 21745254 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA-ABO (50 to 80 U)
Number of subjects: 1740
Study 21745254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1740
Study 21745254 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA-ABO
Number of subjects: 1740
Study 19574236 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin pretreatment
Number of subjects: 41
Study 19574236 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 41
Study 17049140 — intervention group
Group type: EXPERIMENTAL
Intervention: Store-and-forward (SF) teledermatology
Number of subjects: 208
Study 17049140 — intervention group
Group type: COMPARATOR
Intervention: Conventional hospital outpatient consultation
Number of subjects: 208
Study 17049140 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital photography with and without dermoscopy
Number of subjects: 208
Study 17049140 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face consultation
Number of subjects: 208
Study 15318955 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal spray (FPANS)
Number of subjects: 101
Study 15318955 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray (PNS)
Number of subjects: 101
Study 15318955 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroids (FPANS)
Number of subjects: 101
Study 11166493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (20 mg)
Number of subjects: 0
Study 11166493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9476694 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day)
Number of subjects: 26
Study 9476694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 8176575 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler dry powder inhaler
Number of subjects: 10
Study 8176575 — intervention group
Group type: COMPARATOR
Intervention: Metered-dose inhaler with spacer (Nebuhaler)
Number of subjects: 10
Study 2438500 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 40
Study 2438500 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 40
Study 30482701 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (1 mg/kg bolus followed by 2.5 mg/kg/h infusion)
Number of subjects: 50
Study 30482701 — intervention group
Group type: COMPARATOR
Intervention: Heparin (4 mg/kg)
Number of subjects: 50
Study 30482701 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 50